Jove
Visualize
联系我们

相关概念视频

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

225
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
225

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Development of a Blocking ELISA for the Serological Diagnosis of Getah Virus.

Transboundary and emerging diseases·2026
Same author

Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab).

Cancer research communications·2026
Same author

Renal function decline in adults with cystic fibrosis experiencing pulmonary exacerbations.

Annals of the American Thoracic Society·2026
Same author

Social risk factors in patients with cystic fibrosis: impacts on exacerbations, lung function, and BMI.

Therapeutic advances in respiratory disease·2025
Same author

Remotely addressing health-related social needs (ELICIT) in cystic fibrosis: design and implementation of a multicenter screening and intervention quality improvement project.

Therapeutic advances in respiratory disease·2025
Same author

Cutaneous Adverse Effects of Elexacaftor-Tezacaftor-Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis.

Journal of cosmetic dermatology·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Sep 14, 2025

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

10.8K

改进调节器管理和副作用选:一个CF学习网络创新实验室

Kevin P Lonabaugh1, Anna Saulitis2, Elizabeth Boettinger2

  • 1University of Virginia, Charlottesville, Virginia, USA.

Pediatric pulmonology
|July 22, 2025
PubMed
概括

质量改进方法增加了囊性纤维化转膜导电性调节器 (CFTR) 调节器的使用和CF患者的副作用查. 这种方法增强了调节器管理,并确定了常见的,通常未列出的副作用.

关键词:
囊性纤维化症是什么选取 输出 输出 输出 输出 输出 输出模块化器是一个模块化器.质量 改善 提高质量有关副作用的副作用是什么?

更多相关视频

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.4K
A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines
06:59

A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines

Published on: June 22, 2022

2.2K

相关实验视频

Last Updated: Sep 14, 2025

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

10.8K
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.4K
A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines
06:59

A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines

Published on: June 22, 2022

2.2K

科学领域:

  • 肺部病理学 肺部病理学
  • 药理学 药理学是指药理学的学科.
  • 提高质量 提高科学 提高质量

背景情况:

  • 超过90%的囊性纤维化 (PwCF) 患者有资格接受CFTR调节剂,但有12%的人没有服用这些改变生活的疗法.
  • 调节器采用和管理方面的差距促使CF基金会CF学习网络 (CFLN) 启动质量改进 (QI) 倡议.

研究的目的:

  • 调查CFTR调节器在符合条件的PwCF中使用的障碍.
  • 实施和评估调节器启动,管理和副作用选的最佳实践.

主要方法:

  • 31个CF中心使用了改进模型和计划-做-研究-行动周期来调整干预措施.
  • 该研究重点关注两个目标:增加elexacaftor-tezacaftor-ivacaftor/ivacaftor (ETI/I) 的使用或记录的延期,并改善PwCF在ETI上的副作用查率.
  • 数据通过每周提交的中心提交收集,并使用控制和运行图表进行分析.

主要成果:

  • 从2022年12月到2023年5月,评估的PwCF中有98.5%记录了ETI/I使用 (89.3%) 或推迟 (9.2%),而之前的副作用是最常见的推迟原因 (39.0%).
  • 在2024年3月至8月期间,ETI副作用查率从基线67.1%提高到80.8%.
  • 在24.5%的查中发现了潜在的副作用,包括情绪变化,注意力不集中/脑雾和体重增加.

结论:

  • QI方法成功增强了多个CF中心的CFTR调节器管理和副作用查.
  • 通常报告的副作用,有些不列在处方信息中,强调需要谨慎查和管理.
  • 开发的过程和工具是可重复的,适用于未来的CF疗法.